Let’s Talk About Ozempic (Updated Version)
Credibility score: 60/100 — Mostly Credible. Mixed credibility - some claims are solid, others need verification.
BSmeter analyzed "Let’s Talk About Ozempic (Updated Version)" and rated it 60/100 for credibility (a BS score of 40/100 — mostly credible), on 2026-05-19. Its weakest claim — "GLP-1 drugs are the first effective medical treatment for obesity ever" — scored 40/100 and was flagged as dubious. 20 claims were checked against the video transcript. Scores are produced by BSmeter's AI analysis of the transcript, not independent human verification.
Of 20 claims analyzed: 0 scored under 40, 14 between 40 and 69, and 6 at 70 or above.
Claims analyzed
Ozempic/Mounjaro caused obesity rate to drop for first time ever — Dubious (45/100)
At 0:00
Obesity rate drop is real but pinning it solely on these drugs is a stretch
Why this score: Correlation vs causation problem here.
- US obesity rate did dip slightly in recent data, but experts point to multiple factors including post-pandemic shifts and better reporting.
- Attributing the entire historic first drop to GLP-1 drugs ignores how few people were actually on them long enough to move national stats.
Original quote: “In the last few years Ozempic or Mounjaro managed to make millions of people lose massive amounts of weight with seemingly only mild side effects. More than one in eight US adults have tried the drugs, and for the first time in history the country's obesity rate actually fell.”
WHO added GLP-1 drugs to Essential Medicines List and issued obesity guidelines — OK (60/100)
At 0:16
WHO move checks out but the 'first time ever' safety claim is doing heavy lifting
Why this score: WHO addition is accurate but timeline and safety framing need nuance.
- GLP-1 drugs were added to the Essential Medicines List in late 2025 for diabetes.
- Obesity guidelines exist but long-term safety data is still accumulating — not quite the settled science the speaker implies.
Original quote: “At the end of 2025 the WHO added GLP-1 drugs to its Essential Medicines List for diabetics and released guidelines on how to use it for obesity. For the first time ever, we have a medication that reliably, quickly and seemingly safely can make people lose weight.”
GLP-1 drugs are the first effective medical treatment for obesity ever — Dubious (40/100)
At 0:30
Calling it the 'first effective' treatment ignores decades of bariatric surgery and earlier meds. — Overstated history.
Why this score: Historical treatments existed long before GLP-1s. Key issues:
- Bariatric surgeries like gastric bypass have shown 50-70% sustained weight loss since the 1960s
- Earlier drugs (orlistat, phentermine) provided modest but documented results
- GLP-1s are a major advance in convenience, not literally the first effective option
Original quote: “It turns out GLP-1 drugs are the first effective medical treatment for obesity in medical history.”
Half Snickers daily surplus = 10 lbs fat in one year — Dubious (45/100)
At 3:05
Math is off — 10 lbs requires closer to a full Snickers daily surplus.
Why this score: Math doesn't add up. Key issues:
- Half a Snickers (~110 calories) × 365 = ~40,000 calories
- 40,000 calories ≈ 11.5 lbs, not 10 lbs
- Real fat gain is also affected by metabolism adaptation
Original quote: “Just a small excess, like the equivalent of half a snickers over your maintenance calories per day, compounds to almost 5 kg or 10 pounds of fat after a year.”
Most dieters regain weight within 1-2 years and often gain more — Solid (80/100)
At 3:32
✅
Why this score: Well-supported finding.
- Long-term studies show 80%+ regain most weight within 2 years
- Many regain more than lost due to metabolic adaptation
Original quote: “Most people gain back most weight they lose during a diet, within a year or two, and often gain more afterwards.”
Half of US grocery products are ultra-processed and labels mislead on serving sizes — OK (65/100)
At 3:57
Roughly accurate ballpark — exact half is fuzzy but directionally right.
Why this score: Directionally correct but imprecise. Key points:
- USDA and FDA data show ~60% of calories in US diets come from ultra-processed foods
- Serving size labels are regulated but often abused with tiny portions
- 'Half of products' is an estimate, not a strict census
Original quote: “About half of the products in a US grocery store are ultra processed and many are labeled in ways that are deeply misleading, like the serving sizes on packs of chips.”
News outlets split on framing weight-loss drugs as miracle vs harmful — OK (60/100)
At 4:44
True in principle — media bias exists. Still pretty generic.
Why this score: Basic observation about media framing. Accurate but doesn't add new evidence or specific examples.
Original quote: “The same weight-loss drug story might be framed as a miracle by some outlets, while others warn about harmful trends.”
Body fat regulates hunger hormones — Solid (75/100)
At 5:00
✅
Why this score: - Adipose tissue secretes hormones like leptin that influence appetite.
- Excess fat disrupts this signaling, increasing hunger and insulin resistance.
Original quote: “And it turns out your fat is one of the major regulators of this orchestra.”
GLP-1 still works in obese people — Solid (80/100)
At 5:25
✅
Why this score: - GLP-1 is secreted post-meal in both lean and obese individuals.
- Levels are often lower in obesity, but the hormone pathway remains active.
Original quote: “There is one specific hormone that plays its tune quietly in the background, even in obese people – the “glucagon-like peptide-1”, or GLP-1.”
First GLP-1 agonist approved 2005 for diabetes, 2014 for obesity — OK (60/100)
At 6:31
Dates are directionally right but the first one wasn't actually the first GLP-1 agonist. Minor slip.
Why this score: Mostly accurate timeline.
- Exenatide (Byetta) was actually the first GLP-1 receptor agonist, approved in 2005.
- Semaglutide (Ozempic) came later in 2017.
- The speaker is conflating the first drug class member with the first approval year.
Original quote: “The first artificial GLP-1 was approved in 2005 for diabetes and in 2014 for obesity, but the revolution came with semaglutide and tirzepatide – Ozempic and Mounjaro.”
Ozempic/Mounjaro give 10% loss in 3 months, 15% in 6 months, 20%+ in 1 year — Dubious (45/100)
At 6:48
Optimistic averages dressed up as typical results. Real trials show lower numbers and high dropout.
Why this score: Optimistic framing of trial data.
- STEP 1 trial for semaglutide showed ~15% loss at 68 weeks, not 20%+ routinely.
- Many people lose less than 10% or stop early due to side effects.
- 10% in 3 months is possible but far from guaranteed for most users.
Original quote: “On the weight loss side, these drugs are incredibly effective. In 3 months you can lose 10% of your initial weight. Three months later, over 15. And after a year, you may reach more than 20% – a level of weight loss that used to”
GLP-1 drugs can deliver over 20% weight loss in a year — Solid (78/100)
At 8:30
✅
Why this score: Realistic range backed by trials.
- STEP 1 trial showed ~15-16% average loss with semaglutide
- SURMOUNT-1 trial showed 20.9% average loss with tirzepatide at 72 weeks
Original quote: “And after a year, you may reach more than 20% – a level of weight loss that used to only really be achievable through bariatric surgery.”
Semaglutide reduces stroke/heart attack risk by 20% — Solid (85/100)
At 8:43
✅
Why this score: SELECT trial result.
- 20% relative risk reduction in major adverse cardiovascular events
Original quote: “Treatment with semaglutide cuts your risk of stroke or heart attack by 20%.”
Tirzepatide lowers new diabetes risk by 66% — Dubious (52/100)
At 8:58
Half-true at best ⚠️
Why this score: Specific number is odd.
- No large trial shows exactly 66% reduction in 17 months
- SURPASS trials showed strong HbA1c drops but not this exact figure for diabetes prevention
Original quote: “17 months of tirzepatide crashes your chances of developing diabetes by 66%.”
GLP-1 drugs fix sleep apnea, kidneys, liver, inflammation, cancer, Alzheimer's — Dubious (40/100)
At 9:25
Overreaching on several fronts 🙄
Why this score: Mixed evidence.
- Strong data for sleep apnea and kidney protection
- Cancer and Alzheimer's links are still preliminary or ongoing trials
Original quote: “They also reduce sleep apnoea, improve kidney and liver function, lower inflammation, cut cancer risk, and may potentially slow Alzheimer's.”
GLP-1 drugs have been used for decades with millions now on them so new side effects may appear — OK (65/100)
At 10:30
Technically correct timeline but downplays how recent the weight-loss boom really is ⚠️
Why this score: Partially accurate.
- GLP-1 agonists like exenatide date to 2005 and semaglutide to 2017 for diabetes.
- The massive non-diabetic surge only started ~2021-2022, so long-term data for this new population is still limited.
Original quote: “While these drugs are not really that new, since diabetics have been using them for decades, because now millions of people are using them, we might discover new side effects in the coming years.”
GLP-1 drugs without diet control become an unhealthy crash diet — Opinion (55/100)
At 10:50
Fair warning but frames normal use as crash dieting — bit dramatic 🙄
Why this score: Reasonable caution.
- Rapid loss can reduce muscle if protein and training are ignored.
- Calling it a "crash diet" is subjective; many users still eat normal calorie levels.
Original quote: “Apart from this, the main downside of GLP-1 drugs may come from their greatest strength – rapid weight loss. If you don’t actively check what you eat, taking these drugs is just an unhealthy crash diet.”
Weight loss plateaus after ~1 year; 25% regain significantly and 20% regain all — Dubious (45/100)
At 11:10
Numbers feel pulled from somewhere — no source given for the 25% and 20% figures 🚩
Why this score: Numbers don't match major trials.
- STEP 1 trial showed average plateau around week 60-68.
- Real-world regain rates are closer to 60-70% after stopping; the specific 25%/20% split isn't backed by large published data.
Original quote: “After about a year the weight loss slows down and eventually stops in most people. At this point you usually stop using the medication. If you used that time to change your eating habits you have a really good chance of keeping the lost weight off! But about 25% regain a significant chunk, and some…”
Living with obesity is much unhealthier than taking these drugs — Opinion (70/100)
At 11:30
Common medical view but still depends on individual risk-benefit — not universal truth
Why this score: Context matters.
- Obesity raises risks for diabetes, heart disease, and joint issues.
- GLP-1 side effects are generally milder, but long-term data beyond 2-3 years remains limited.
Original quote: “Based on what we know today, it seems pretty clear that living with obesity is much unhealthier than living with the drugs.”
Patents on semaglutide and tirzepatide expiring soon, prices will crash — Dubious (45/100)
At 12:30
Soon is doing a lot of work here — actual expirations are still years away.
Why this score: Timeline is optimistic. Key issues:
- Core US patents for semaglutide run into 2032-2033
- Generic entry in many countries is still 2026-2028 at earliest
- Price drops will happen but not overnight
Original quote: “Patents for the semaglutide and tirzepatide will expire soon in many countries and prices for them will collapse as a result.”
See the full analysis with timestamps →